NICE® gives you an accurate insight into your pregnancy

From a simple blood draw as early as 10 weeks into your pregnancy, NICE® screens for the most common chromosomal abnormalities that can affect your developing baby's future. This test is done with little or no risk to your pregnancy.

Overview

  • A simple blood test to screen for chromosomal abnormalities of the developing baby. Carries little or no risk to your pregnancy.

  • Can be performed as early as on the 10th week of pregnancy. Twin pregnancy can be tested.

  • Employs Whole Genome Sequencing method for comprehensive coverage of all chromosomes.

  • More than 99% accuracy rate.

  • Can be performed as early as 10 weeks. Pregnancies with twins can be accepted.

  • Option to know your baby’s gender.

  • Tested by internationally certified laboratory in South Korea.

  • 2 panels available to detect 3 conditions (T21, T18, T13). Option to know your baby's gender.

  • Up to US$ 300 confirmatory testing subsidy for patients detected with high risk of chromosomal abnormalities.

Conventional Prenatal Tests vs NICE® NIPT

Conventional maternal marker-based prenatal tests such as triple tests, quad tests and integrated tests carry a high false positive rate of 5% or more. This means that of those who were diagnosed as high risk through these tests, only 2 to 3 percent of them actually have Down syndrome. The rest of the group are perfectly normal but were misdiagnosed as part of the high risk group.

More accurate test reduce need for unnecessary invasive prenatal test

As high risk group patients are usually required to go through risky invasive test such as amniotic fluid test for confirmation, which exposes them to the risk of side effects including miscarriage, choosing a more reliable and accurate test will spare expectant mothers from unnecessary agony and anxiety. The table below compares the various prenatal tests available in the market today.

NICE® Conventional Serum Tests Confirmatory Tests
Detection Rate (T21) >99% 80% - 95% 99.99%
False Positive Rate (T21) 1.49% 3-5% less than 1%
Possible risk No (non-invasive) No (non-invasive) Yes (invasive)
Specimen 10ml of blood 5ml of blood Amniotic fluid or chorionic cells
Test period As early as 10 weeks 10- 22 weeks 10 - 20 weeks
Test method Next generation sequencing Serum biochemical markers Cultivation using amniotic fluid or chorionic cells
Turnaround time 10 – 14 working days 4 – 5 weeks 2 – 3 weeks
Source:
1. Practice Bulletin No. 163: Screening for Fetal Aneuploidy; American college of Obstetrics & Gynaecologists. 127(5):e123–e137, May 2016.
2. Kim MJ, Chang HK, Kim DI, Hee SU, Park S, Kim JH, Bae JS, Lee MH, Lee MS. Validation of fetus aneuploidy in 221 Korean clinical samples using non-invasive chromosome examination; J Genet Med 2015;12(2):79-84, May 2015.
3. Non-Invasive Prenatal Testing (NIPT) Factsheet; National Coalition for Health Professional education in Genetics, 21 November 2012.

Enrolling NICE® NIPT

NICE® NIPT must be prescribed by your obstetrician who will explain the details about NIPT to ensure the test is suitable for you. Please enquire with your obstetrician today or fill out the form below:



Name:*
This field is required

Email Address:*
Email address is required

Contact Number*
Contact number is required

Doctor's Name:*
This field is required

Delivery Hospital*
Invalid Input

Estimated date of delivery:*
Estimated date of delivery is required

Country of Delivery*
Please choose country of delivery

Invalid Input
I consent to Genscreen and its related corporations (collectively, the “Cordlife Group”) to contact me about products/services and promotions/updates offered by Cordlife Group, via calls/SMS/emails.


Disclaimer
No test is perfect. DNA test results do not provide a definitive genetic risk in all individuals. Cell-free DNA does not replace the accuracy and precision of prenatal diagnosis with CVS or amniocentesis. Patients with positive test result or an additional finding should be referred for genetic counselling and offered invasive prenatal diagnosis for confirmation of test results. A negative test result does not ensure an unaffected pregnancy. The absence of an additional finding does not indicate a negative result. While results of this testing is highly accurate, not all chromosomal abnormalities may be detected due to placental, maternal or fetal mosaicism, or other causes. The healthcare provider is responsible for the use of this information in the management of their patient.

NIPT is a screening, not a diagnostic test. Patients should opt for it only as an informed choice after appropriate pre-test counselling.